Peter Kraft

Prof. Peter Kraft


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MLMengzhen Liu
Mengzhen Liu
YJYu Jiang
Yu Jiang
RWRobbee Wedow
Robbee Wedow
YLYue Li
Yue Li
DBDavid M. Brazel
David M. Brazel
HPHunt All-In Psychiatry
Hunt All-In Psychiatry

23 October 2017 in Nature
Verified
Journal Article
Open access
PDF file
KMKyriaki Michailidou
Kyriaki Michailidou
SLSara Lindström
Sara Lindström
JDJoe Dennis
Joe Dennis
JBJonathan Beesley
Jonathan Beesley
SHShirley Hui
Shirley Hui
DEDouglas F. Easton
Douglas F. Easton
Association analysis identifies 65 new breast cancer risk loci, predicts target genes for known risk loci and demonstrates a strong overlap with somatic driver genes in breast tumours. Genome-wide association studies for breast cancer have identified common genetic variation that influences susceptibility to this disease, but much of the genetic risk remains unexplained. Doug Easton and colleagues report a genome-wide association study for breast cancer in more than 122,000 cases and 105,000 controls. The authors genotyped a subset of these cases using OncoArray, a new, custom genome-wide single-nucleotide polymorphism (SNP) array for cancer genomics. Overall, they identify 65 loci newly associated with breast cancer susceptibility, and estimate that, together with 107 previously identified breast cancer susceptibility loci, these explain about 18 per cent of the familial relative risk of breast cancer. Polygenic risk scores may be used in risk prediction models and may improve early detection and targeted prevention of the disease. Breast cancer risk is influenced by rare coding variants in susceptibility genes, such as BRCA1, and many common, mostly non-coding variants. However, much of the genetic contribution to breast cancer risk remains unknown. Here we report the results of a genome-wide association study of breast cancer in 122,977 cases and 105,974 controls of European ancestry and 14,068 cases and 13,104 controls of East Asian ancestry1. We identified 65 new loci that are associated with overall breast cancer risk at P < 5 × 10−8. The majority of credible risk single-nucleotide polymorphisms in these loci fall in distal regulatory elements, and by integrating in silico data to predict target genes in breast cells at each locus, we demonstrate a strong overlap between candidate target genes and somatic driver genes in breast tumours. We also find that heritability of breast cancer due to all single-nucleotide polymorphisms in regulatory features was 2–5-fold enriched relative to the genome-wide average, with strong enrichment for particular transcription factor binding sites. These results provide further insight into genetic susceptibility to breast cancer and will improve the use of genetic risk scores for individualized screening and prevention.

1 October 2015 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
BVBjarni J. Vilhjálmsson
Bjarni J. Vilhjálmsson
JYJian Yang
Jian Yang
HFHilary K. Finucane
Hilary K. Finucane
AGAlexander Gusev
Alexander Gusev
SLSara Lindström
Sara Lindström
WZWei Zheng
Wei Zheng

1 January 2019 in The American Journal of Human Genetics
Verified
Journal Article
Open access
NMNasim Mavaddat
Nasim Mavaddat
KMKyriaki Michailidou
Kyriaki Michailidou
JDJoe Dennis
Joe Dennis
MLMichael Lush
Michael Lush
LFLaura Fachal
Laura Fachal
DEDouglas F. Easton
Douglas F. Easton
Stratification of women according to their risk of breast cancer based on polygenic risk scores (PRSs) could improve screening and prevention strategies. Our aim was to develop PRSs, optimized for prediction of estrogen receptor (ER)-specific disease, from the largest available genome-wide association dataset and to empirically validate the PRSs in prospective studies. The development dataset comprised 94,075 case subjects and 75,017 control subjects of European ancestry from 69 studies, divided into training and validation sets. Samples were genotyped using genome-wide arrays, and single-nucleotide polymorphisms (SNPs) were selected by stepwise regression or lasso penalized regression. The best performing PRSs were validated in an independent test set comprising 11,428 case subjects and 18,323 control subjects from 10 prospective studies and 190,040 women from UK Biobank (3,215 incident breast cancers). For the best PRSs (313 SNPs), the odds ratio for overall disease per 1 standard deviation in ten prospective studies was 1.61 (95%CI: 1.57-1.65) with area under receiver-operator curve (AUC) = 0.630 (95%CI: 0.628-0.651). The lifetime risk of overall breast cancer in the top centile of the PRSs was 32.6%. Compared with women in the middle quintile, those in the highest 1% of risk had 4.37- and 2.78-fold risks, and those in the lowest 1% of risk had 0.16- and 0.27-fold risks, of developing ER-positive and ER-negative disease, respectively. Goodness-of-fit tests indicated that this PRS was well calibrated and predicts disease risk accurately in the tails of the distribution. This PRS is a powerful and reliable predictor of breast cancer risk that may improve breast cancer prevention programs.

18 April 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LSLifeLines Cohort Study
LifeLines Cohort Study
AOAysu Okbay
Aysu Okbay
BBBart M L Baselmans
Bart M L Baselmans
JNJan-Emmanuel De Neve
Jan-Emmanuel De Neve
PTPatrick Turley
Patrick Turley
DCDavid Cesarini
David Cesarini
Daniel Benjamin, Meike Bartels, Philipp Koellinger and colleagues report a genome-wide association meta-analysis of subjective well-being, depressive symptoms and neuroticism. The study leverages a large sample size together with genetic correlations between the phenotypes to identify, with high confidence, loci associated with each phenotype. Very few genetic variants have been associated with depression and neuroticism, likely because of limitations on sample size in previous studies. Subjective well-being, a phenotype that is genetically correlated with both of these traits, has not yet been studied with genome-wide data. We conducted genome-wide association studies of three phenotypes: subjective well-being (n = 298,420), depressive symptoms (n = 161,460), and neuroticism (n = 170,911). We identify 3 variants associated with subjective well-being, 2 variants associated with depressive symptoms, and 11 variants associated with neuroticism, including 2 inversion polymorphisms. The two loci associated with depressive symptoms replicate in an independent depression sample. Joint analyses that exploit the high genetic correlations between the phenotypes (|ρ^| ≈ 0.8) strengthen the overall credibility of the findings and allow us to identify additional variants. Across our phenotypes, loci regulating expression in central nervous system and adrenal or pancreas tissues are strongly enriched for association.

5 January 2016 in JAMA
Verified
Journal Article
Open access
PDF file
LMLorelei A. Mucci
Lorelei A. Mucci
JHJacob Hjelmborg
Jacob Hjelmborg
JHJennifer R. Harris
Jennifer R. Harris
KCKamila Czene
Kamila Czene
DHDavid J. Havelick
David J. Havelick
JKJaakko Kaprio
Jaakko Kaprio
The global burden of cancer is considerable, with an estimated 12 million new cases and 8 million cancer deaths each year.1 In 2015 in the United States, 1.7 million individuals will be diagnosed with cancer and 590 000 will die of cancer, accounting for 1 in 4 deaths.2 In the Nordic countries, cancer is the leading cause of mortality, accounting for 30% of all deaths. Refinement of primary and secondary prevention strategies (ie, factors that would have the greatest influence on reducing cancer incidence and mortality) requires a detailed understanding of the contribution of genetic and environmental factors to disease pathogenesis.